Bangladesh Medical Research Council (BMRC)
32 patients of denovo-ANLL were treated with Doxorubicin, Ara-C and 6- Mercaptopurine (DAM) regimen. Remission induction was instituted with 1-3 cycles of DAM regimen and maintenance was given by 6-MP continuously with intermittent DA (1,5) regimen. In the remission induction, Doxorubicin 30 mg/m2 for 3 days, Ara C 150mg/m2for 5 days and 6-Mp 100mg/m2daily was given. Complete remission (CR) was observed in 60% cases. The probability of 2 years disease-free survival of patients with complete remission is 56.73%.